Cancer Franchise

Arana has a number of anti-cancer compounds in its pipeline that warrant further development, based on the results from discovery stage and pre-clinical studies.

The market for all anti-cancer drugs is worth more than US$20 billion annually. The market for a drug against any one solid tumour is estimated to be approximately US$500 million in per annum sales.

The lung cancer market alone is estimated to be worth US$3 billion annually, and the market for melanoma is worth around US$1 billion.